Strengthen the investigation of the cross-talk mechanism between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease

doi:10.3877/cma.j.issn.2095-2015.2024.05.001

Abstract

Abstract:

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with inflammatory bowel disease (IBD) is significantly increased, but it remains unclear whether the two diseases are co-existence or extraintestinal manifestations of IBD. Largely, IBD and MASLD share common molecular regulatory mechanisms and potential therapeutic targets, but the causal relationship and potential interplay of MASLD and IBD is not well elucidated. This article reviews the current understanding of the prevalence, clinical course and pathogenesis of MASLD in IBD, especially calls attention to both the cross-talk mechanism study.

Key words: Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Metabolic dysfunction-associated steatotic liver disease, Cross-talk mechanism

Li Chen, Changqing Yang, Fengshang Zhu. Strengthen the investigation of the cross-talk mechanism between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 385-389.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.05.001

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I05/385

References 36

[1]	Maresca R, Mignini I, Varca S, et al. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together[J]. Int J Mol Sci, 2024, 25(6): 3278.
[2]	Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21(11): 719-733.
[3]	Navarro P, Gutiérrez-Ramírez L, Tejera-Muñoz A, et al. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease[J]. Nutrients, 2023, 15(21): 4507.
[4]	Dias E, Andrade P, Lopes S, et al. Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study[J]. Ann Gastroenterol, 2023, 36(1): 54-60.
[5]	Trifan A, Stafie R, Rotaru A, et al. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter[J]. J Clin Med, 2022, 11(19): 5959.
[6]	Kodali A, Okoye C, Klein D, et al. Crohn's Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review[J]. Cureus, 2023, 15(8): e42995.
[7]	Aggarwal M, Garg R, Parthasarthy G, et al. Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease[J]. Dig Dis Sci, 2023, 68(3): 1006-1015.
[8]	Martínez-Domínguez SJ, García-Mateo S, Laredo V, et al. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review[J]. Cancers(Basel), 2023, 15(13): 3367.
[9]	Boustany A, Rahhal R, Mitri J, et al. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review[J]. Eur J Gastroenterol Hepatol, 2023, 35(10): 1067-1074.
[10]	Hyun HK, Lee HW, Park J, et al. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease[J]. Gut Liver, 2024, 18(2): 294-304.
[11]	Ritaccio G, Stoleru G, Abutaleb A, et al. Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare[J]. Dig Dis Sci, 2021, 66(9): 3186-3191.
[12]	Zhong Z, Xu M, Ge C, et al. Exploring shared molecular signatures and regulatory mechanisms in nonalcoholic steatohepatitis and inflammatory bowel disease using integrative bioinformatics analysis[J]. Sci Rep, 2024, 14(1): 12085.
[13]	Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease[J]. J Crohns Colitis, 2016, 10(3): 239-54.
[14]	Beheshti Maal A, Shahrbaf MA, Sadri B, et al. Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1. 7 Million Patients[J]. J Crohns Colitis, 2024, 18(3): 360-374.
[15]	Khrom M, Long M, Dube S, et al. Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease[J]. Gastroenterology, 2024, 167(2): 315-332.
[16]	Noorian S, Jeon Y, Nguyen MT, et al. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis[J]. Inflamm Bowel Dis, 2022, 28(6): 878-887.
[17]	Zhang Q, Liu S, Wu J, et al. Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study[J]. Chin Med J(Engl), 2024, 137(14): 1705-1714.
[18]	Chen J, Dan L, Tu X, et al. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study[J]. Hepatol Int, 2023, 17(1): 202-214.
[19]	Shu Y, Yang B, Liu X, et al. Causal effects from inflammatory bowel disease on liver function and disease: a two-sample Mendelian randomization study[J]. Front Med(Lausanne), 2024, 10: 1320842.
[20]	Chen L, Fan Z, Sun X, et al. Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease[J]. Front Pharmacol, 2022, 13: 891410.
[21]	Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors[J]. Clin Gastroenterol Hepatol, 2023, 21(2): 406-414.
[22]	Nagata T, Funakoshi S, Morihara D, et al. Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study[J]. Intest Res, 2023, 21(4): 471-480.
[23]	Adolph TE, Meyer M, Jukic A, et al. Heavy arch: from inflammatory bowel diseases to metabolic disorders[J]. Gut, 2024, 73(8): 1376-1387.
[24]	Michaudel C, Danne C, Agus A, et al. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases[J]. Gut, 2023, 72(7): 1296-1307.
[25]	Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy[J]. J Crohns Colitis, 2019, 13(5): 541-554.
[26]	Magrì S, Paduano D, Chicco F, et al. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history[J]. World J Gastroenterol, 2019, 25(37): 5676-5686.
[27]	Maitiabula G, Tian F, Wang P, et al. Liver PP2A-Cα Protects From Parenteral Nutrition-associated Hepatic Steatosis[J]. Cell Mol Gastroenterol Hepatol, 2022, 14(3): 669-692.
[28]	Hunt JE, Billeschou A, Windeløv JA, et al. Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2- dependent pathway in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(5): G980-G987.
[29]	Mai H, Yang X, Xie Y, et al. The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease[J]. Front Microbiol, 2024, 14: 1257903.
[30]	De Caro C, Spagnuolo R, Quirino A, et al. Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study[J]. Int J Mol Sci, 2024, 25(10): 5453.
[31]	Zhu G, Chen L, Liu S, et al. Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats[J]. Heliyon, 2022, 8(7): e09872.
[32]	Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(11): 3002-3014.
[33]	Hwang N, Kang D, Shin SJ, et al. Creeping fat exhibits distinct Inflammation-specific adipogenic preadipocytes in Crohn's disease[J]. Front Immunol, 2023, 14: 198905.
[34]	Besharat S, Sakhavi F, Sookhtehsaraei P, et al. Non-alcoholic fatty liver disease(NAFLD) and obesity in inflammatory bowel disease(IBD) patients in Gorgan[J]. Caspian J Intern Med, 2024, 15(2): 299-306.
[35]	Trivedi HD, Lopes EW, Glissen Brown J, et al. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis[J]. J Clin Gastroenterol, 2023, 57(6): 610- 616.
[36]	Perez-Carreras M, Casis-Herce B, Rivera R, et al. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach[J]. World J Gastroenterol, 2021, 27(41): 7113-7124.

Please choose a citation manager

Content to export